TVAMP
INO icon

Tennessee Valley Asset Management Partners’s Inovio Pharmaceuticals INO Stock Holding History

Tennessee Valley Asset Management Partners’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8
Closed -$51 – 407
2023
Q4 		$51 Buy
+8
New +$39 ﹤0.01% 810

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Tennessee Valley Asset Management Partners's INO Position: Q1 2024 in Review

Tennessee Valley Asset Management Partners sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 8 shares — an estimated $51 sold.

Tennessee Valley Asset Management Partners first reported a position in INO in Q4 2023 and held it in 1 quarter. The position peaked at $51 in Q4 2023. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

  • Tennessee Valley Asset Management Partners reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Tennessee Valley Asset Management Partners sold 8 Inovio Pharmaceuticals shares in Q1 2024, an estimated $51.
  • Tennessee Valley Asset Management Partners first reported a position in Inovio Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Tennessee Valley Asset Management Partners's Inovio Pharmaceuticals position peaked at $51 in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Tennessee Valley Asset Management Partners's 13F filing for Q1 2024, filed 23 Apr 2024.